HOME >> BIOLOGY >> NEWS
Nanoparticle probes are destined for major new role in medical diagnostics and drug delivery

The emerging miniaturized world known as nanomedicine integrates technology, biology and medicine using tools and materials constructed from molecular- and atomic-sized particles too small to seen with a conventional laboratory microscope. Shuming Nie, PhD, professor of biomedical engineering at Emory University and the Georgia Institute of Technology, and director of cancer nanotechnology at Emory's Winship Cancer Institute, will highlight exciting technological breakthroughs in nanomedicine at the annual meeting of the American Association for the Advancement of Science (AAAS) in Seattle. Dr. Nie's talk on "Bioconjugated Nanoparticles for Personalized Medicine: Molecular Imaging, Profiling and Drug Targeting" will be part of a two-day Nanotechnology Seminar at the meeting.

The science of nanotechnology is rapidly moving from its early beginnings in electronics, computers and telecommunications into the expanding field of biomedical nanotechnology. Dr. Nie has been a leader in the nanomedicine field, and has developed semiconductor nanoparticles called quantum dots, which can be bound to particular genes and proteins and used as markers for molecular diagnostics and drug delivery.

"Biomedical nanotechnology is leading to major advances in molecular diagnostics, therapeutics, molecular biology and bioengineering," Dr. Nie says. "Scientists have begun to develop functional nanoparticles that are linked to biological molecules such as peptides, proteins and DNA."

By virtue of their miniature size nanoparticles assume special properties that distinguish them from larger particles, including the ability to emit light in different colors and to act as fluorescent tags. This makes them highly suitable as contrast agents for magnetic resonance imaging (MRI), positron emission tomography (PET) or as fluorescent tracers in optical microscopy. They also may be useful as structural scaffold in tissue engineering.

Although nanoparticles are similar
'"/>

Contact: Ron Sauder
rsauder@emory.edu
404-727-3366
Emory University Health Sciences Center
13-Feb-2004


Page: 1 2

Related biology news :

1. Nanoparticles illuminate brain tumors for days under MRI
2. Nanoparticles could aid biohazard detection, computer industry
3. Nanoparticles in air bad news for people
4. Microarrays, key genome expression trackers, work better when probes are sequence-verified
5. Study probes ecosystem of tree holes
6. UCLA chemists develop new coating for nanoscale probes
7. Shark guide probes uncharted waters
8. Purdue research suggests nanotubes could make better brain probes
9. Carnegie Mellon University receives NASA award to develop probes to detect life on Mars
10. MIT team probes arsenic and old lakes
11. MIT probes cartilage on nanoscale

Post Your Comments:
(Date:11/4/2014)... (Nov. 4, 2014) – A majority of Madagascar,s 101 ... could have serious consequences for the rainforests they call ... the positive impacts lemurs can have on rainforest tree ... disappearance could have on the region,s rich biodiversity. , ... fruits eaten by lemurs. Lemurs in turn disperse ...
(Date:11/3/2014)... DUBLIN , Nov. 3, 2014 Research ... report "Cell Therapy - Technologies, Markets and Companies" ... evaluates cell therapy technologies and methods, which have already started ... Hematopoietic stem cell transplantation is replacing the old fashioned bone ... described. Cell therapy is bound to become a part of ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
(Date:11/21/2014)... 20, 2014 The report, ... Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, ... Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to ... drivers, threats, opportunities, and challenges. , Browse ... spread through 185 pages and in-depth TOC ...
(Date:11/21/2014)... Why did Stephen Hawking become so famous? ... recognizable? Why have they become icons to rival film ... Ratcliffe seeks out the answers to those questions, and ... with science. In " Stephen Hawking Smoked My Socks ... Ratcliffe puts it plainly: , “It is profoundly ...
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
(Date:11/21/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A have ... ended September 30, , Nine-months ended September ... 2014 , 2013 , 2014 , ... , 6,715 , 14,476 Gross profit , ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
Cached News: